Strides Pharma Science subsidiary avails of credit facility from South African bank
Strides Pharma stock rises21-12-2023
21-12-2023
Strides Pharma Science Ltd - 532531 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (LODR) Read With SEBI Circular No. SEBI/ HO/ CFD/ CFD-Pod-1/ P/ CIR/ 2023/ 123 Dated July 13, 2023
Intimation under Regulation 30 of SEBI LODR read with SEBI Circular dated July 13, 202321-12-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 - Dipak Ratilal Shah & Mukesh Ratilal Shah19-12-2023
Strides Pharma Science Ltd - 532531 - Strides Associate Company - Stelis Biopharma Announces Closure Of Its Transaction With Syngene International Limited
Strides associate company - Stelis Biopharma announces closure of its transaction with Syngene International Limited01-12-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal01-12-2023
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC to Shankar Murthy28-11-2023
Strides Pharma's subsidiary gets USFDA approved, shares up
The shares were up by 0.67 per cent to 489.70 at 10 am on the BSE23-11-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Generic Suprep Bowel Prep Kit23-11-2023
Strides Pharma secures USFDA approval for Levetiracetam, shares up
The oral solution will be manufactured in Bengaluru21-11-2023
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Levetiracetam Oral Solution21-11-2023